Choosing Injectafer Banner

Are your adult IDA

Are your adult IDA patients getting the iron repletion they need?

When oral iron fails, it’s time to consider IV iron. Many iron deficiency anemia (IDA) patients have iron deficits up to 1500 mg or more.1 With Injectafer, infuse less often and replete more iron. Injectafer offers evidence-based dosing, up to 1500 mg of iron in just 2 administrations, separated by at least 7 days. With Injectafer administrations, 100% of the iron enters the patient’s bloodstream.

 Injectafer IV iron infusion dosing Injectafer IV iron infusion dosing
  • For adult patients weighing less than 50 kg (110 lb), give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course of treatment.
  • When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not <2 mg of iron per mL and administer over at least 15 minutes. When administered as a slow IV push, give at the rate of approximately 100 mg (2 mL) per minute.

Evidence-based dosing:

Many IDA patients have iron deficits of approximately 1500 mg1

Injectafer dosing chart and patient population dataInjectafer dosing chart and patient population data

Calculated iron deficit based on the modified Ganzoni formula: Subject weight in kg x (15 - current hemoglobin g/dL) x 2.4 + 500. If subject TSAT >20% and ferritin >50 ng/mL, the 500-mg constant is not needed.

§Reported etiologies included chronic kidney disease, uterine bleeding, GI-related conditions, postpartum causes, and other/unknown.

||Reported etiologies included heavy uterine bleeding, GI disorders, postpartum causes, nutritional or dietary deficiency, and other.

Injectafer is a dextran-free

Injectafer is a dextran-free formulation of colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron9

  • The chemical characteristic of the iron-carbohydrate complex means that iron is released slowly, avoiding toxicity and oxidative stress
 Iron infusion carboxymaltose molecule  Iron infusion carboxymaltose molecule

Worldwide experience

  • Injectafer has been studied in more than 40 clinical trials with over 8300 patients treated worldwide10
  • Approved in over 70 countries since initial EU approval in 200710

DOWNLOAD THE GETTING STARTED BROCHURE

DOWNLOAD THE INJECT CHECKLIST

Download Now

Choosing Injectafer Page Navigation

Specialty Specific Content

Important Safety Information

INDICATIONS

Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.

WARNINGS AND PRECAUTIONS

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.

In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.

In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.

ADVERSE REACTIONS

In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).

The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.

To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see Full Prescribing Information.

Choosing Injectafer References

Site global Footer